Cardiovascular Revascularization Medicine
Volume 8, Issue 4 , Pages 259-274 , October 2007

Efficacy and safety of pimecrolimus-eluting stents in porcine coronary arteries

  • Ron Waksman

      Affiliations

    • Cardiovascular Research Institute, Washington Hospital Center, Washington DC, USA
    • Corresponding Author InformationCorresponding author. Washington Hospital Center, 110 Irving Street, NW, Suite 4B-1, Washington DC, 20010, USA. Tel.: +1 202 877 2812; fax: +1 202 877 2715.
    • ,
  • Rajbabu Pakala

      Affiliations

    • Cardiovascular Research Institute, Washington Hospital Center, Washington DC, USA
    • ,
  • Richard Baffour

      Affiliations

    • Cardiovascular Research Institute, Washington Hospital Center, Washington DC, USA
    • ,
  • David Hellinga

      Affiliations

    • Cardiovascular Research Institute, Washington Hospital Center, Washington DC, USA
    • ,
  • Rufus Seabron

      Affiliations

    • Cardiovascular Research Institute, Washington Hospital Center, Washington DC, USA
    • ,
  • Fermin O. Tio

      Affiliations

    • Biomedical Research Foundation of South Texas, San Antonio, TX, USA
    • ,
  • Eric Wittchow

      Affiliations

    • Vascular Interventions R&D group, BIOTRONIK GmbH & Co. KG., Erlangen, Germany
    • ,
  • Michael Tittelbach

      Affiliations

    • Vascular Interventions R&D group, BIOTRONIK GmbH & Co. KG., Erlangen, Germany
    • ,
  • Tobias Diener

      Affiliations

    • Vascular Interventions R&D group, BIOTRONIK GmbH & Co. KG., Erlangen, Germany
    • ,
  • Claus Harder

      Affiliations

    • Vascular Interventions R&D group, BIOTRONIK GmbH & Co. KG., Erlangen, Germany
    • ,
  • Renu Virmani

      Affiliations

    • CV Path, Gaithersburg, MD, USA
    • ,
  • Russel Jones

      Affiliations

    • CV Path, Gaithersburg, MD, USA

Received 19 September 2007 ,Accepted 19 September 2007.

References 

  1. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31:224–230
  2. Hayashi S, Watanabe N, Nakazawa K, Suzuki J, Tsushima K, Tamatani T, et al. Roles of P-selectin in inflammation, neointimal formation, and vascular remodeling in balloon-injured rat carotid arteries. Circulation. 2000;102:1710–1717
  3. Okamoto E, Couse T, De Leon H, Suzuki J, Tsushima K, Tamatani T, et al. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation. 2001;104:2228–2235
  4. Breuss JM, Cejna M, Bergmeister H, Kadl A, Baumgartl G, Steurer S, et al. Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation. 2002;105:633–638
  5. Zhou Z, Lauer MA, Wang K, Forudi F, Zhou X, Song X, et al. Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. Atherosclerosis. 2002;161:153–159
  6. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974–2980
  7. Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?. J Am Coll Cardiol. 1996;28:345–353
  8. Serrano CV, Ramires JA, Venturinelli M, Arie S, D'Amico E, Zweier JL, et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol. 1997;29:1276–1283
  9. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol. 2001;21:327–334
  10. Schillinger M, Exner M, Mlekusch W, Haumer M, Ahmadi R, Rumpold H, et al. Balloon angioplasty and stent implantation induce a vascular inflammatory reaction. J Endovasc Ther. 2002;9:59–66
  11. Bhatia V, Bhatia R, Dhindsa M. Drug-eluting stents: new era and new concerns. Postgrad Med J. 2004;80:13–18
  12. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852–855
  13. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. Novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999;141:264–273
  14. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol. 2003;17:493–503
  15. Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res. 1998;290:501–507
  16. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267–274
  17. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 2004;63:617–624
  18. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001;104:473–479
  19. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol. 2004;44:1373–1385
  20. Schwartz RS, Edelman ER, Carter A, Chronos N, Rogers C, Robinson KA, et al. Consensus Committee. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation. 2002;106:1867–1873
  21. Taylor A. Metals. In:  Sigwart U editors. Endoluminal stenting. London: W.B. Saunders Company, Ltd; 1996;p. 28–33
  22. Haudrechy P. Nickel release from 304 and 316 stainless steels in synthetic sweat. Comparison with nickel and nickel-plated metals. Consequences on allergic contact dermatitis. Corros Sci. 1993;35:329–336
  23. Park JB, Kim YK. Metallic biomaterials. In:  Park JB,  Bronzino JD editor. Biomaterials principles and applications. Boca Raton: CRC Press; 2003;p. 1–20
  24. Kereiakes DJ, Cox DA, Hermiller JB, Midei MG, Bachinsky WB, Nukta ED, et al. Guidant Multi-Link Vision Stent Registry Investigators. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol. 2003;92:463–466
  25. Gotman I. Characteristics of metals used in implants. J Endourol. 1997;11:383–389
  26. Granchi D, Ciapetti G, Savarino L, Cavedagna D, Donati ME, Pizzoferrato A. Assessment of metal extract toxicity on human lymphocytes cultured in vitro. J Biomed Mater Res. 1996;31:183–191
  27. Ermolli M, Menné C, Pozzi G, Serra MA, Clerici LA. Nickel, cobalt and chromium-induced cytotoxicity and intracellular accumulation in human hacat keratinocytes. Toxicology. 2001;159:23–31
  28. Bolz A, Schaldach M. Artificial heart valves: improved blood compatibility by PECVD a-SiC:H coating. Artif Organs. 1990;14:260–269
  29. Monnink SH, van Boven AJ, Peels HO, Tigchelaar I, de Kam PJ, Crijns HJ, et al. Silicon-carbide coated coronary stents have low platelet and leukocyte adhesion during platelet activation. J Investig Med. 1999;47:304–310
  30. Kalnins U, Erglis A, Dinne I, Kumsars I, Jegere S. Clinical outcomes of silicon carbide coated stents in patients with coronary artery disease. Med Sci Monit. 2002;8:PI16–PI20
  31. Köster R, Vieluf D, Kiehn M, Sommerauer M, Kähler J, Baldus S, et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet. 2000;356:1895–1897
  32. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation. 2004;109:701–705
  33. Revell PA, Braden M, Freeman MA. Review of the biological response to a novel bone cement containing poly (ethyl methacrylate) and n-butyl methacrylate. Biomaterials. 1998;19:1579–1586
  34. Niemi SM, Fox JG, Brown LR, Langer R. Evaluation of ethylene-vinyl acetate copolymer as a non-inflammatory alternative to Freund's complete adjuvant in rabbits. Lab Anim Sci. 1985;35:609–612
  35. Peltonen LI, Jero J, Sukura A, Pietola L, Konttinen YT, Aarnisalo AA. Biocompatibility of polylactides in the middle ear: an experimental animal study. Otol Neurotol. 2007;28:850–853
  36. Schmidmaier G, Baehr K, Mohr S, Kretschmar M, Beck S, Wildemann B. Biodegradable polylactide membranes for bone defect coverage: biocompatibility testing, radiological and histological evaluation in a sheep model. Clin Oral Implants Res. 2006;17:439–444
  37. Agrawal CM, Haas KF, Leopold DA, Clark HG. Evaluation of poly (l-lactic acid) as a material for intravascular polymeric stents. Biomaterials. 1992;13:176–182
  38. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102:399–404
  39. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22:1769–1776
  40. Colombo A, Sangiorgi G. The monocyte: the key in the lock to reduce stent hyperplasia?. J Am Coll Cardiol. 2004;43:24–26
  41. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation. 1998;98:224–233
  42. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44–52
  43. Welt FG, Edelman ER, Simon DI, Rogers C. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler Thromb Vasc Biol. 2000;20:2553–2558
  44. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol. 1996;16:1312–1318
  45. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci U S A. 1998;95:10134–10139
  46. Mori E, Komori K, Yamaoka T, Tanii M, Kataoka C, Takeshita A, et al. Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation. 2002;105:2905–2910
  47. Meingassner JG, Aschauer H, Stuetz A, Billich A. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp Dermatol. 2005;14:752–757
  48. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002;46:228–241
  49. Aramburu J, Rao A, Klee CB. Calcineurin: from structure to function. Curr Top Cell Regul. 2000;36:237–295
  50. Shibasaki F, Hallin U, Uchino H. Calcineurin as a multifunctional regulator. J Biochem (Tokyo). 2002;131:1–15
  51. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol. 1997;15:707–747
  52. Liu Z, Dronadula N, Rao GN. A novel role for nuclear factor of activated T cells in receptor tyrosine kinase and G-protein-coupled receptor agonist-induced vascular smooth muscle cell motility. J Biol Chem. 2004;279:41218–41226
  53. Yellaturu CR, Ghosh SK, Rao RK, Jennings LK, Hassid A, Rao GN. A potential role for nuclear factor of activated T-cells in receptor tyrosine kinase and G-protein-coupled receptor agonist-induced cell proliferation. Biochem J. 2002;368:183–190
  54. Yu H, Sliedregt-Bol K, Overkleeft H, van der Marel GA, van Berkel TJC, Biessen EAL. Therapeutic potential of a synthetic peptide inhibitor of nuclear factor of activated T cells as Antirestenotic Agent. Arterioscler Thromb Vasc Biol. 2006;26:1531–1537
  55. Salu K, Liu X, Li S, Wang L, Verbeken E, Bosmans J, et al. Methotrexate loaded SAE coated coronary stents reduce neointimal hyperplasia in a porcine coronary model. Heart. 2004;90:195–199
  56. Wang L, Salu K, Verbeken E, Bosmans J, Van de Werf F, De Scheerder I, et al. Stent mediated methylprednisolone delivery reduces macrophage contents and in-stent neointimal formation. Coron Artery Dis. 2005;16:237–243
  57. Salu KJ, Bosmans JM, Huang Y, Hendriks M, Verhoeven M, Levels A, et al. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model. Cardiovasc Res. 2006;69:536–544
  58. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188–1193
  59. Carter AJ, Brodeur A, Collingwood R, Ross S, Gibson L, Wang CA, et al. Experimental efficacy of an everolimus eluting cobalt chromium stent. Catheter Cardiovasc Interv. 2006;68:97–103
  60. Hong MK, Kornowski R, Bramwell O, Ragheb AO, Leon MB. Paclitaxel-coated Gianturco-Roubin II (GR II) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coron Artery Dis. 2001;12:513–515
  61. Jabara R, Chronos N, Tondato F, Conway D, Molema W, Park K, et al. Toxic vessel reaction to an absorbable polymer-based paclitaxel-eluting stent in pig coronary arteries. J Invasive Cardiol. 2006;18:383–390
  62. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation. 2004;109:2168–2171
  63. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004;24:1266–1271
  64. Jander S, Sitzer M, Schumann R, Schroeter M, Siebler M, Steinmetz H, et al. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke. 1998;29:1625–1630
  65. De Palma R, Del Galdo F, Abbate G, Chiariello M, Calabró R, Forte L, et al. Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism. Circulation. 2006;113:640–646
  66. Clausell N, de Lima VC, Molossi S, Liu P, Turley E, Gotlieb AI, et al. Expression of tumour necrosis factor alpha and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy. Br Heart J. 1995;73:534–539
  67. Osada M, Takeda S, Ogawa R, Komori S, Tamura K. T lymphocyte activation and restenosis after percutaneous transluminal coronary angioplasty. J Interferon Cytokine Res. 2001;21:219–221
  68. Andersen HO, Hansen BF, Holm P, Stender S, Nordestgaard BG. Effect of cyclosporine on arterial balloon injury lesions in cholesterol-clamped rabbits: T lymphocyte-mediated immune responses not involved in balloon injury-induced neointimal proliferation. Arterioscler Thromb Vasc Biol. 1999;19:1687–1694

PII: S1553-8389(07)00304-1

doi: 10.1016/j.carrev.2007.09.003

Cardiovascular Revascularization Medicine
Volume 8, Issue 4 , Pages 259-274 , October 2007

Article Tools

* Image Usage & Resolution